GlassScriptPhysician profile
Eddie C Beal
NPI 1265644207
$7,252.81
in general payments reported to CMS, 2019-2025
27 companies · $758 in 2025
The $758 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $113 · 2021: $1,499 · 2022: $1,030 · 2023: $1,417 · 2024: $1,576 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,639 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,639.48 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,578.81 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,418.18 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $804.41 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $685.35 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $472.92 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $318.71 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $276.18 | 2019-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $233.66 | 2021-2023 | |
| Tris Pharma INC | $214.88 | 2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Sunovion Pharmaceuticals INC. | $167.05 | 2019-2022 | |
| Alkermes, INC. | $149.63 | 2019-2023 | Aristada, Lybalvi |
| Eisai INC. | $147.92 | 2021 | |
| Corium, LLC | $143.42 | 2022-2024 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $136.23 | 2021-2025 | Qelbree |
| Indivior INC. | $125.49 | 2022-2023 | Perseris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $75.32 | 2023-2025 | Auvelity |
| Allergan, INC. | $75.00 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $47.58 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.02 | 2023-2025 | Trintellix |
| Novo Nordisk INC | $25.43 | 2025 | Ozempic, Rybelsus |
| Acadia Pharmaceuticals INC | $25.16 | 2024 | Nuplazid |
| Tempus Ai, INC | $22.67 | 2024 | |
| Idorsia Pharmaceuticals US INC | $20.65 | 2023 | Quviviq |
| Owp Pharmaceuticals, INC. | $19.99 | 2024 | Subvenite |
| Shire North American Group INC | $18.04 | 2019 | |
| Merck Sharp & Dohme LLC | $12.33 | 2019 | |
| Neuronetics, INC. | $3.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eddie Beal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.